{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:50:52Z","timestamp":1795229452135,"version":"4.10.3"},"reference-count":105,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Homozygous deletions in the gene encoding methylthioadenosine phosphorylase (MTAP) occur in \u223c10% of patients with cancer, including up to 45% in some tumor types, and may be associated with poor prognosis. MTAP deficiency causes accumulation of its catabolic target methylthioadenosine (MTA) that outcompetes S-adenosyl methionine (SAM) for binding to protein arginine methyltransferase 5 (PRMT5), partially inhibiting PRMT5 activity as a posttranslational regulator of a variety of critical cellular functions. Prior anticancer treatments developed to target PRMT5 exhibited high rates of dose-limiting hematologic toxicities because of a lack of selectivity for tumor cells. More recently, several agents have been developed that exploit the vulnerability of MTAP-deleted cancer cells to further inhibition of the PRMT5 pathway, selectively inducing synthetic lethality in those cancer cells. MTA-cooperative PRMT5 inhibitors such as BMS-986504\/MRTX1719 and AMG 193 target the PRMT5\u2013MTA complex, whereas inhibitors of the SAM synthetase methionine adenosyl transferase 2A, such as IDE397, deprive PRMT5 of its methyl donor SAM. In this review article, we summarize the mechanisms of action, preclinical data, and clinical data available thus far for these novel classes of oncology precision medicine and discuss potential future directions relevant to MTAP deletion as a promising synthetic lethal vulnerability for cancer therapy.<\/jats:p>","DOI":"10.1158\/0008-5472.can-25-2126","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:43:10Z","timestamp":1767991390000},"page":"1558-1569","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["<i>MTAP<\/i>\n                    Deletion in Oncogenesis: A Synthetic Lethality Scenario"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rodon","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Investigational Cancer Therapeutics, Division of Cancer Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":false,"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"2Lung Cancer Research, Sarah Cannon Research Institute, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9667-9833","authenticated-orcid":false,"given":"Ben","family":"George","sequence":"additional","affiliation":[{"name":"3Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-0443","authenticated-orcid":false,"given":"Pooja A.","family":"Shah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Investigational Cancer Therapeutics, Division of Cancer Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-8427","authenticated-orcid":false,"given":"Kathryn C.","family":"Arbour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 4 Department of Medicine, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026040203074645100_bib1","doi-asserted-by":"crossref","first-page":"695770","DOI":"10.3389\/fonc.2021.695770","article-title":"Homozygous co-deletion of type I interferons and CDKN2A genes in thoracic cancers: potential consequences for therapy","volume":"11","author":"Grard","year":"2021","journal-title":"Front Oncol"},{"key":"2026040203074645100_bib2","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"2026040203074645100_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","article-title":"Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA","volume":"13","author":"Cortes-Ciriano","year":"2023","journal-title":"Cancer Discov"},{"key":"2026040203074645100_bib4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"2026040203074645100_bib5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"2026040203074645100_bib6","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.7150\/ijbs.67149","article-title":"Downregulation of MTAP promotes tumor growth and metastasis by regulating ODC activity in breast cancer","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2026040203074645100_bib7","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","article-title":"MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization","volume":"12","author":"Hansen","year":"2022","journal-title":"Sci Rep"},{"key":"2026040203074645100_bib8","first-page":"6639","article-title":"Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a\/ARF), acts as a tumor suppressor in a breast cancer cell line","volume":"62","author":"Christopher","year":"2002","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1534\/g3.114.014555","article-title":"Expression of MTAP inhibits tumor-related phenotypes in HT1080 cells via a mechanism unrelated to its enzymatic function","volume":"5","author":"Tang","year":"2014","journal-title":"G3 (Bethesda)"},{"key":"2026040203074645100_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.13587","article-title":"MTAP deficiency contributes to immune landscape remodelling and tumour evasion","volume":"168","author":"Chang","year":"2023","journal-title":"Immunology"},{"key":"2026040203074645100_bib11","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1158\/1078-0432.CCR-09-1511","article-title":"Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors","volume":"15","author":"Huang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026040203074645100_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ejso.2014.04.017","article-title":"MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients","volume":"40","author":"Su","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2026040203074645100_bib13","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/0008-5472.CAN-18-1010","article-title":"MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation","volume":"79","author":"Hansen","year":"2019","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib14","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1158\/0008-5472.CAN-20-0414","article-title":"MTAP deficiency-induced metabolic reprogramming creates a vulnerability to cotargeting de novo purine synthesis and glycolysis in pancreatic cancer","volume":"81","author":"Hu","year":"2021","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0304-4165(81)90024-6","article-title":"Dependence of adenine production upon polyamine synthesis in cultured human lymphoblasts","volume":"675","author":"Kamatani","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"2026040203074645100_bib16","doi-asserted-by":"crossref","first-page":"105492","DOI":"10.1016\/j.jbc.2023.105492","article-title":"Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition","volume":"300","author":"Bedard","year":"2024","journal-title":"J Biol Chem"},{"key":"2026040203074645100_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"2026040203074645100_bib18","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","article-title":"Human SWI\/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes","volume":"24","author":"Pal","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2026040203074645100_bib19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nsmb.1568","article-title":"PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"2026040203074645100_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review","volume":"5","author":"Feustel","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"2026040203074645100_bib21","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0960-9822(01)00592-9","article-title":"Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln","volume":"11","author":"Meister","year":"2001","journal-title":"Curr Biol"},{"key":"2026040203074645100_bib22","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1093\/emboj\/cdf585","article-title":"Assisted RNP assembly: SMN and PRMT5 complexes cooperate in the formation of spliceosomal UsnRNPs","volume":"21","author":"Meister","year":"2002","journal-title":"EMBO J"},{"key":"2026040203074645100_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1083\/jcb.200702147","article-title":"Two distinct arginine methyltransferases are required for biogenesis of Sm-class ribonucleoproteins","volume":"178","author":"Gonsalvez","year":"2007","journal-title":"J Cell Biol"},{"key":"2026040203074645100_bib24","doi-asserted-by":"crossref","first-page":"ra58","DOI":"10.1126\/scisignal.2001936","article-title":"Protein arginine methyltransferase 5 regulates ERK1\/2 signal transduction amplitude and cell fate through CRAF","volume":"4","author":"Andreu-P\u00e9rez","year":"2011","journal-title":"Sci Signal"},{"key":"2026040203074645100_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncb2158","article-title":"Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation","volume":"13","author":"Hsu","year":"2011","journal-title":"Nat Cell Biol"},{"key":"2026040203074645100_bib26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ncb1802","article-title":"Arginine methylation regulates the p53 response","volume":"10","author":"Jansson","year":"2008","journal-title":"Nat Cell Biol"},{"key":"2026040203074645100_bib27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1074\/mcp.M112.020743","article-title":"A method for large-scale identification of protein arginine methylation","volume":"11","author":"Uhlmann","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"2026040203074645100_bib28","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1074\/mcp.O113.032748","article-title":"Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest","volume":"13","author":"Sylvestersen","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"2026040203074645100_bib29","doi-asserted-by":"crossref","first-page":"eaat8388","DOI":"10.1126\/scisignal.aat8388","article-title":"Proteomics profiling of arginine methylation defines PRMT5 substrate specificity","volume":"12","author":"Musiani","year":"2019","journal-title":"Sci Signal"},{"key":"2026040203074645100_bib30","doi-asserted-by":"crossref","first-page":"820226","DOI":"10.3389\/fncel.2022.820226","article-title":"PRMT5 interacting partners and substrates in oligodendrocyte lineage cells","volume":"16","author":"Dansu","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"2026040203074645100_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1369\/0022155413475452","article-title":"Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer","volume":"61","author":"Bao","year":"2013","journal-title":"J Histochem Cytochem"},{"key":"2026040203074645100_bib32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.humpath.2014.02.013","article-title":"Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial\u2013mesenchymal transition","volume":"45","author":"Ibrahim","year":"2014","journal-title":"Hum Pathol"},{"key":"2026040203074645100_bib33","doi-asserted-by":"crossref","first-page":"14847","DOI":"10.18632\/oncotarget.14682","article-title":"Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status","volume":"8","author":"Kumar","year":"2017","journal-title":"Oncotarget"},{"key":"2026040203074645100_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3892\/ijo.2017.3833","article-title":"The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy","volume":"50","author":"Shimizu","year":"2017","journal-title":"Int J Oncol"},{"key":"2026040203074645100_bib35","doi-asserted-by":"crossref","first-page":"1010428317695917","DOI":"10.1177\/1010428317695917","article-title":"Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer","volume":"39","author":"Wu","year":"2017","journal-title":"Tumour Biol"},{"key":"2026040203074645100_bib36","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1093\/nar\/gkp516","article-title":"PRMT5 is required for cell-cycle progression and p53 tumor suppressor function","volume":"37","author":"Scoumanne","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2026040203074645100_bib37","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1101\/gad.606110","article-title":"PRMT5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency","volume":"24","author":"Tee","year":"2010","journal-title":"Genes Dev"},{"key":"2026040203074645100_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat Chem Biol"},{"key":"2026040203074645100_bib39","doi-asserted-by":"crossref","first-page":"39963","DOI":"10.18632\/oncotarget.18102","article-title":"Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers","volume":"8","author":"Prabhu","year":"2017","journal-title":"Oncotarget"},{"key":"2026040203074645100_bib40","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026040203074645100_bib41","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.celrep.2019.02.001","article-title":"PRMT5 modulates splicing for genome integrity and preserves proteostasis of hematopoietic stem cells","volume":"26","author":"Tan","year":"2019","journal-title":"Cell Rep"},{"issue":"Suppl 7","key":"2026040203074645100_bib42","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1016\/j.annonc.2022.07.585","article-title":"456MO METEOR-1: a phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors","volume":"33","author":"Postel-Vinay","year":"2022","journal-title":"Ann Oncol"},{"issue":"Suppl 16","key":"2026040203074645100_bib43","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2023.41.16_suppl.3008","article-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)","volume":"41","author":"Monga","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026040203074645100_bib44","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026040203074645100_bib45","doi-asserted-by":"crossref","first-page":"106634","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral Oncol"},{"key":"2026040203074645100_bib46","doi-asserted-by":"crossref","first-page":"102961","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"key":"2026040203074645100_bib47","doi-asserted-by":"crossref","first-page":"20406207241275376","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"2026040203074645100_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2020.00621","article-title":"PRMT5 is required for T cell survival and proliferation by maintaining cytokine signaling","volume":"11","author":"Tanaka","year":"2020","journal-title":"Front Immunol"},{"key":"2026040203074645100_bib49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1535-7163.MCT-19-0189","article-title":"Selective PRMT5 inhibitors suppress human CD8+ T cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA","volume":"19","author":"Strobl","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026040203074645100_bib50","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5\u2022MTA complex for the treatment of MTAP-deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem"},{"key":"2026040203074645100_bib51","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"2026040203074645100_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov"},{"key":"2026040203074645100_bib53","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2026040203074645100_bib54","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1016\/j.annonc.2024.08.671","article-title":"604O Phase I dose escalation and initial dose expansion results of AMG 193: a MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors","volume":"35","author":"Sacher","year":"2024","journal-title":"Ann Oncol"},{"key":"2026040203074645100_bib55","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J Med Chem"},{"key":"2026040203074645100_bib56","doi-asserted-by":"crossref","first-page":"114668","DOI":"10.1016\/j.ejca.2024.114668","article-title":"146 (PB134): first disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies","volume":"211","author":"Smith","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026040203074645100_bib57","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J Med Chem"},{"issue":"Suppl 6","key":"2026040203074645100_bib58","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1538-7445.AM2024-3319","article-title":"Abstract 3319: the MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers","volume":"84","author":"Waters","year":"2024","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib59","doi-asserted-by":"crossref","first-page":"102264","DOI":"10.1016\/j.tranon.2024.102264","article-title":"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers","volume":"52","author":"Briggs","year":"2025","journal-title":"Transl Oncol"},{"key":"2026040203074645100_bib60","doi-asserted-by":"crossref","first-page":"114672","DOI":"10.1016\/j.ejca.2024.114672","article-title":"150 (PB138): AZD3470 induces regressions and durable responses in MTAPdeficient tumor models of diverse tumor indications","volume":"211","author":"Urosevic","year":"2024","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"2026040203074645100_bib61","doi-asserted-by":"crossref","first-page":"LB008","DOI":"10.1158\/1538-7445.AM2024-LB008","article-title":"Abstract LB008: integrative dynamic MultiOMICs analysis identifies cell cycle and DNA damage response phenotypes as downstream consequences of using the PRMT5 inhibitor AZD3470","volume":"84","author":"Hong","year":"2024","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.08.018","article-title":"Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma","volume":"32","author":"Braun","year":"2017","journal-title":"Cancer Cell"},{"key":"2026040203074645100_bib63","doi-asserted-by":"crossref","first-page":"112965","DOI":"10.1016\/j.isci.2025.112965","article-title":"The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing","volume":"28","author":"Fowler","year":"2025","journal-title":"iScience"},{"key":"2026040203074645100_bib64","doi-asserted-by":"crossref","first-page":"114981","DOI":"10.1016\/j.ejca.2024.114981","article-title":"503LBA LBA Orals: results from CA240-0007, a phase 1\/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)","volume":"211","author":"Rodon","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026040203074645100_bib65","article-title":"Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in MTAP deleted non-small cell lung cancer and urothelial cancer","author":"Herzberg"},{"key":"2026040203074645100_bib66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","article-title":"MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial","volume":"16","author":"Gounder","year":"2025","journal-title":"Nat Commun"},{"issue":"8_Suppl_2","key":"2026040203074645100_bib67","doi-asserted-by":"crossref","first-page":"CT079","DOI":"10.1158\/1538-7445.AM2025-CT079","article-title":"Abstract CT079: pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)","volume":"85","author":"Rod\u00f3n","year":"2025","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib68","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"2026040203074645100_bib69","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1021\/acs.jmedchem.0c01895","article-title":"Discovery of AG-270, a first-in-class oral MAT2A inhibitor for the treatment of tumors with homozygous MTAP deletion","volume":"64","author":"Konteatis","year":"2021","journal-title":"J Med Chem"},{"key":"2026040203074645100_bib70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"Suppl 13","key":"2026040203074645100_bib71","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1538-7445.AM2021-1278","article-title":"Abstract 1278: MAT2A inhibitor, IDE397, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts","volume":"81","author":"Fischer","year":"2021","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib72","doi-asserted-by":"crossref","article-title":"The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP\u2212\/\u2212 tumors","author":"Garbett","DOI":"10.1016\/j.ejca.2024.114734"},{"issue":"Suppl 7","key":"2026040203074645100_bib73","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1538-7445.AM2023-1644","article-title":"Abstract 1644: dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer","volume":"83","author":"Fischer","year":"2023","journal-title":"Cancer Res"},{"issue":"Suppl 7","key":"2026040203074645100_bib74","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1538-7445.AM2023-1637","article-title":"Abstract 1637: MAT2A inhibition in MTAP\u2212\/\u2212 tumors confers mechanistic vulnerabilities to multiple clinically actionable synthetic lethal drug combinations","volume":"83","author":"Gerrick","year":"2023","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-020-57812-2","article-title":"MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab","volume":"10","author":"Jing","year":"2020","journal-title":"Sci Rep"},{"key":"2026040203074645100_bib76","doi-asserted-by":"crossref","first-page":"178","DOI":"10.18632\/oncotarget.28376","article-title":"Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss","volume":"14","author":"Bou Zerdan","year":"2023","journal-title":"Oncotarget"},{"key":"2026040203074645100_bib77","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun"},{"key":"2026040203074645100_bib78","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","volume":"12","author":"Ashok Kumar","year":"2023","journal-title":"Cancer Med"},{"key":"2026040203074645100_bib79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"issue":"Suppl 16","key":"2026040203074645100_bib80","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1200\/JCO.2024.42.16_suppl.8599","article-title":"Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC","volume":"42","author":"Thummalapalli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"2026040203074645100_bib81","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1158\/1538-7445.AM2024-4588","article-title":"Abstract 4588: combination of MTA-cooperative PRMT5 inhibitor and direct mutant-selective KRAS inhibitors as a novel therapeutic approach for MTAP-deficient pancreatic cancer","volume":"84","author":"Drizyte-Miller","year":"2024","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib82","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of resistance to anti-EGFR therapy in colorectal cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"2026040203074645100_bib83","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Suppl 6","key":"2026040203074645100_bib84","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1158\/1538-7445.AM2024-4536","article-title":"Abstract 4536: MTAP loss alters the epigenetic landscape and demonstrates superior therapeutic sensitivity to concomitant PRMT5 and PARP inhibition in cholangiocarcinoma","volume":"84","author":"Shah","year":"2024","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib85","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.euo.2021.10.006","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"Suppl 16","key":"2026040203074645100_bib86","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1200\/JCO.2024.42.16_suppl.3067","article-title":"Nature and distribution of methyl thioadenosine phosphorylase (MTAP) genomic loss in human tumors","volume":"42","author":"Necchi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026040203074645100_bib87","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"2026040203074645100_bib88","doi-asserted-by":"crossref","first-page":"109.e15","DOI":"10.1016\/j.urolonc.2022.10.001","article-title":"Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss","volume":"41","author":"Basin","year":"2023","journal-title":"Urol Oncol"},{"key":"2026040203074645100_bib89","doi-asserted-by":"crossref","first-page":"e009600","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026040203074645100_bib90","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2026040203074645100_bib91","doi-asserted-by":"crossref","first-page":"1758835920923424","DOI":"10.1177\/1758835920923424","article-title":"Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis","volume":"12","author":"Chae","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2026040203074645100_bib92","doi-asserted-by":"crossref","first-page":"100055","DOI":"10.1016\/j.esmogo.2024.100055","article-title":"Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin\/gemcitabine: a systematic review and meta-analysis","volume":"4","author":"Digklia","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"Suppl 6","key":"2026040203074645100_bib93","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1158\/1538-7445.AM2024-4636","article-title":"Abstract 4636: genome-wide drug anchor screens identify CAAP1 and AKAP17A as regulators of PRMT5 inhibitor sensitivity","volume":"84","author":"Yoda","year":"2024","journal-title":"Cancer Res"},{"key":"2026040203074645100_bib94","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod Pathol"},{"key":"2026040203074645100_bib95","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/PAS.0000000000002297","article-title":"Prevalence of S-methyl-5\u2032-thioadenosine phosphorylase (MTAP) deficiency in human cancer: a tissue microarray study on 13,067 tumors from 149 different tumor types","volume":"48","author":"Gorbokon","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 1","key":"2026040203074645100_bib96","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/blood-2023-174445","article-title":"Epigenetic silencing of MTAP in Hodgkin\u2019s lymphoma renders it sensitive to a 2nd generation PRMT5 inhibitor","volume":"142","author":"Urosevic","year":"2023","journal-title":"Blood"},{"key":"2026040203074645100_bib97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/his.14324","article-title":"Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma","volume":"78","author":"Chapel","year":"2021","journal-title":"Histopathology"},{"key":"2026040203074645100_bib98","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/mog2.70","article-title":"The biological essence of synthetic lethality: bringing new opportunities for cancer therapy","volume":"3","author":"Ge","year":"2024","journal-title":"MedComm Oncol"},{"key":"2026040203074645100_bib99","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2026040203074645100_bib100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2026040203074645100_bib101","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/jcm12020709","article-title":"KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration","volume":"12","author":"Yang","year":"2023","journal-title":"J Clin Med"},{"key":"2026040203074645100_bib102","doi-asserted-by":"crossref","first-page":"806851","DOI":"10.3389\/fbioe.2022.806851","article-title":"Spectrum of BRAF aberrations and its potential clinical implications: insights from integrative pan-cancer analysis","volume":"10","author":"Yi","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2026040203074645100_bib103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cac2.12005","article-title":"Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis","volume":"40","author":"Liu","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"2026040203074645100_bib104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"2026040203074645100_bib105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-2126\/3725073\/can-25-2126.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/7\/1558\/3753316\/can-25-2126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/7\/1558\/3753316\/can-25-2126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:08:05Z","timestamp":1775113685000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/7\/1558\/775627\/MTAP-Deletion-in-Oncogenesis-A-Synthetic-Lethality"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":105,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-2126","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}